secwatch.observer — SEC 8-K summary
======================================

Issuer:     REPLIGEN CORP (RGEN)
CIK:        0000730272
Form:       8-K
Filed at:   2026-02-24T23:59:59+00:00
Accession:  0001193125-26-065246
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Repligen Q4 revenue $198M (+18%); FY26 guidance $810-840M
---------------------------------------------------------

- Q4 revenue $198M, up 18% reported and 14% organic YoY; full year 2025 revenue $738M (+16% reported and organic non-COVID).
- Q4 GAAP EPS $0.23 vs ($0.60); adjusted EPS $0.49 vs $0.44. Full year adjusted EPS $1.71 vs $1.58.
- FY26 revenue guidance $810M–$840M (10-14% reported, 9-13% organic); adjusted operating margin expansion of 150 bps at midpoint.
- Full year 2025 organic growth of 14% exceeded initial guidance range; adjusted operating margins improved 90 bps YoY.
- CEO cited strong finish led by Analytics and Proteins; new office in Singapore and product launches in Q4.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/730272/000119312526065246/0001193125-26-065246-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/730272/000119312526065246/rgen-20260224.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-065246

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer